# Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening

> **NCT00469781** · PHASE4 · COMPLETED · sponsor: **Center For Excellence In Eye Care** · enrollment: 95 (actual)

## Conditions studied

- Cystoid Macular Edema,
- Retinal Thickening

## Interventions

- **DRUG:** 2. Xibrom (Bromfenac)
- **DRUG:** 1. Pred Forte

## Key facts

- **NCT ID:** NCT00469781
- **Lead sponsor:** Center For Excellence In Eye Care
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2008-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00469781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00469781, "Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00469781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*